US pharma major Eli Lilly (NYSE: LLY) has revealed it suing spas, wellness centers and compounding pharmacies selling unapproved and compounded versions of its type 2 diabetes drug Mounjaro (tirzepatide).
Lilly said it filed this lawsuit to protect patients, declaring: “Lilly cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not our own branded product.”
Though not yet approved for the management of weight loss, tirzepatide has shown significant efficacy in the treatment of obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze